Hannah Blau, MBBS **UPDATED**
April 2020
46

CURRICULUM VITAE

Name: Hannah Blau, MBBS **ID No**.: 05071032-6

Faculty/Dept:
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel/Pediatrics

Hospital/Dept:
Pediatric Pulmonary Institute
Schneider Children's Medical Center of Israel
Petach Tikva 49 202
Israel **Phone No**.: +972-3-925-3654

Home Address:
2 Hamaayan Street
Raanana 43569, Israel **Mobile**: +972-+50-4057141
Email: hblau@post.tau.ac.il

Date & Place of Birth: 9th July 1951, Israel

Date of Arrival in Israel: 23.5.77 [migrated to Australia in 1953]

Marital Status: Married, 4 children

A. EDUCATION

PERIODS OF STUDIES

1969-1974 **MBBS Medical degree**
Melbourne University, Melbourne, Australia
Subject: Medicine [Honors Award in Biology, Surgery, Biochemistry, Physiology, Pathology, Pharmacology, Microbiology]
Date Awarded: 1974
MD License No.: 13196

1982 **Pediatrics Diploma**
Specialist License No. 6718

1989 **Adult Pulmonology Diploma**
Specialist License No. 10453

1994 **Pediatric Pulmonology Diploma**
Specialist License No. 13649

1977-1982 Pediatrics Diploma, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1985-1987 Fellowship, Pediatric Pulmonary, Stony Brook University, New York, USA

1988 Specialization Adult Pulmonology, Sapir Medical Center (Meir Hospital), Kfar Saba, Israel

ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS

ACADEMIC EXPERIENCE:

1987-1994 Instructor, Pediatrics,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1994-2003 Lecturer, Pediatrics,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

2003-2008 Senior Lecturer, Pediatrics,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

2008-2018 Associate Professor, Pediatrics,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

2018 – present Full Professor, Pediatrics
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

PROFESSIONAL EXPERIENCE:

1977-1982 Resident, Department of Pediatrics, Sheba Medical Center, Tel Hashomer, Israel; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1982-1985 Senior, attending, Department of Pediatrics A and Lung Clinic, Sheba Medical Center, Tel Hashomer, Israel; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1985-1987 Fellowship, Department of Pediatric Pulmonology, Schneider Children's Hospital, Long Island Jewish Medical Center, New York, USA

1988 Resident, Department of Pulmonology, Sapir Medical Center, Meir Hospital, Israel; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1988-1995 Senior Physician, Pediatric Pulmonology, Beilinson Hospital and Schneider Children's Medical Center of Israel, Petach Tikva, Israel; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

1995-2008 Founding Director, Pediatric Pulmonology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

2008- 2018 Director, Institute of Pediatric Pulmonology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

March 2019- Retired as Director. Continuing as senior physician, Institute of Pulmonology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

MEMBERSHIP IN PROFESSIONAL SOCIETIES

MEMBERSHIP IN PROFESSIONAL SOCIETIES

1996- present American Thoracic Society
1996- present European Respiratory Society
1996- present European Cystic Fibrosis Society & Member of the Standardisation Committee Microbiology Working group

1977- present Israel Medical Association
1988- present Israel Society for Pediatric Pulmonology
1988- present Israel Association of Clinical Pediatrics
1995- present Israel Association for Ambulatory Pediatrics
2007- present Israel Society of Cystic Fibrosis [Secretary from 2008 onwards]

MEMBERSHIP OF INTERNATIONAL COMMITTEES

2008- present Committee of the Pediatric Assembly, Infection and immunology Subcommittee of the European Respiratory Society

2009- present International Relations Committee of the Pediatric Assembly of the American Thoracic Society

2011-2012 Annual Conference Program Committee of the American Thoracic Society

2014- present International Member of the Data Safety Monitoring Board for the CF Foundation, USA – monitoring industry sponsored multicenter clinical trials

2014- present Member of the Working Group for Newborn Screening of the European CF Society

2014- present Member of the Diagnostic Working Group of the European CF Society, and author of the Standards of Practice for Induced Sputum

2015- 2018 PI for the Graub CF Center, Schneider Children's Med Center and member of the steering committee of the Clinical Trials Network of the European Cystic Fibrosis Society]

Ongoing Projects

- *Leading the national effort to promote newborn screening for CF in Israel*
- *Collaborating on National Guidelines for Cystic Fibrosis care*
- *Epidemiologic research involving the Clalit Health Fund data registry, in particular investigating pediatric asthma seasonality and effect of therapeutic interventions*
- *Investigating the use of the Lung Clearance Index for assessing pediatric lung disease*
- *Emerging infections in cystic fibrosis, focus now on Achromobacter xylosoxidans*
- *Efficacy of induced sputum in non-expectorating young children as an indication of lower respiratory track infection, in comparison with bronchoalveolar lavage, writing and promoting international standards of practice for use of this outcome measure in international trials*
- *Inhaled antibiotic therapy of children with non-CF chronic purulent lung disease*

SCIENTIFIC PUBLICATIONS

A. BOOKS AND MONOGRAPHS

1. Blau H.
Cystic fibrosis lung disease: interplay of a microbial microcosm and extremes of inflammation.
Isr Med Assoc J. 2006;8:58-9. *[Editorial]*
IMAJ has replaced above:
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036)

B.1. ORIGINAL ARTICLES **Author H Index (Scopus): 32**

B.1. Original Articles Published

1. Sack J, Blau H, Goldfarb D, Ben Zaray S, Katznelson D.
Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements - a study of 16 patients in Israel.
Isr J Med Sci. 1980;16:417-9.
IMAJ has replaced above:
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. of Citations: 12)

2. Blau H, Katznelson D.
Meconium Ileus - a survey of 23 cases.
Harefuah. 1981;100:411-3.

3. Sack J, Blau H, Amado O, Katznelson D.
Thyroid function in cystic fibrosis patients compared with healthy Israeli children.
Isr J Med Sci. 1983;19:17-9.
IMAJ has replaced above:
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. of Citations: 3)

4. Blau H, Passwell JH, Levanon M, Davidson J, Kohen F, Ramot B.
Studies on human milk macrophages: effect of activation on phagocytosis and secretion of prostaglandin E2 and lysozyme.
Pediatr Res. 1983;17:241-5.
(PEDIATRICS Q1, 17/121, IF 2.882, No. of Citations: 21)

5. Bujanover Y, Peled Y, Blau H, Yahav J, Katznelson D, Gilat T.
Methane production in patients with cystic fibrosis.
J Pediatr Gastroenterol Nutr. 1987;6:377-80.
(PEDIATRICS Q1, 18/121, IF 2.799, No. of Citations: 9)

6. Bujanover Y, Harel A, Geter R, Blau H, Yahav J, Spirer Z.
The development of the chymotryptic activity during postnatal life using the bentiromide test.
Int J Pancreatol. 1988;3:53-8.
(No. of Citations: 3)

7. Blau H, Guzowski DE, Siddiqi ZA, Scarpelli EM, Bienkowski RS.
Fetal type 2 pneumocytes form alveoloar-like structures and maintain long-term differentiation on extracellular matrix.
J Cell Physiol. 1988;136:203-14.
(PHYSIOLOGY Q1, 16/84, IF 4.080, No. of Citations: 52)

8. Fink G, Kay C, Blau H, Spitzer S.
Assessment of exercise capacity in asthmatic children with various degrees of activity.
Pediatr Pulmonol. 1993;15:41-3.
(PEDIATRICS Q1, 19/120, IF 2.758), No. of Citations: 32)

9. Kalina M, Riklis S, Blau H.
Pulmonary epithelial cell proliferation in primary culture of alveolar type II cells.
Exp Lung Res. 1993;19:153-75.
(RESPIRATORY Q4, 54/59, IF 1.394, No. of Citations: 28)

10. Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, Blau H, Ben Tur L, Szeinberg A, Kerem E, Gazit E.
Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+10kb C-T mutation.
Lancet. 1993;342(8862):25-6.
(MEDICINE, GENERAL & INTERNAL 2/155, IF 47.831, No. of Citations: 102)

11. Blau H, Riklis S, Kravtsov V, Kalina M.
Secretion of cytokines by rat alveolar epithelial cells: possible regulatory role for surfactant-associated Protein A.
Am J Physiol. (Lung Cell Mol Physiol.) 1994;266:L148-55.
(PHYSIOLOGY Q1, 12/84, IF 4.281, No. of Citations: 36)

12. Ginsberg G, Blau H, Kerem E, Springer C, Kerem BS, Ackstein E, Greenberg A, Kolumbos A, Abeliovich D, Gazit E, Yahav Y.
Cost-benefit analysis of a national screening program for cystic fibrosis in an Israeli population.
Health Econ. 1994;3:5-23.
(HEALTH CARE SCIENCES & SERVICES, Q2, 34/87, IF 2.301, No. of Citations: 26)

13. Yosipovitch G, Reis J, Tur E, Blau H, Harell D, Morduchowicz G, Boner G.
Sweat electrolytes in patients with advanced renal failure.
J Lab Clin Med. 1994;124(6):808-12.
Continued as Trans Res.
(MEDICINE, RESEARCH AND EXPERIMENTAL Q1, 20/124, IF 4.577, No. of Citations: 9)

14. Kalina M, Blau H, Riklis S, Kravtsov V.
Interaction of surfactant protein A with bacterial lipopolysaccharide may affect some biological functions.
Am J Physiol. (Lung Cell Mol Physiol.) 1995;268:L144-51.
(PHYSIOLOGY Q1, 12/84, IF 4.281, No. of Citations: 59)

15. Augarten A, Hacham S, Kerem E, Kerem BS, Szeinberg A, Laufer J, Doolman R, Altshuler R, Blau H, Bentur L, Gazit E, Katznelson D, Yahav Y.
The significance of sweat Cl/Na ratio in patients with borderline sweat tests.
Pediatr Pulmonol. 1995;20:369-71.
(PEDIATRICS Q1, 19/120, IF 2.758), No. of Citations: 24)

16. Kerem E, Kalman YM, Yahav Y, Shoshani T, Abeliovich D, Szeinberg A, Rivlin J, Blau H, Tal A, Ben-Tur L, Springer A, Augarten A, Godfrey S, Lerer I, Branski D, Friedman M, Kerem B.
Highly variable incidence of cystic fibrosis and different mutations.
Hum Genet. 1995;96:193-7.
(GENETICS AND HEREDITY Q1, 28/167, IF 4.637, No. of Citations: 49)

17. Blau H, Riklis S, Van Iwaarden JF, McCormack FX, Kalina M.
Nitric oxide production by rat alveolar macrophages can be modulated in vitro

Nitric oxide production by rat alveolar macrophages can be modulated in vitro by surfactant protein A.
Am J Physiol. (Lung Cell Mol Biol.) 1997;272(6 Pt 1):L1198-204.
(PHYSIOLOGY Q1, 12/84, IF 4.281, No. of Citations: 59)

18. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I.
Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes.
J Allergy Clin Immunol. 1998;101:464-9.
(ALLERGY Q1, 1/26, IF 13.081, No. of Citations: 45)

19. Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, Bentur L, Springer C, Vila Y, Branski D, Kerem B, Kerem E.
Clinical and genetic risk factors for cystic fibrosis-related liver disease.
Pediatrics. 1999;103:52-7.
(PEDIATRICS Q1, 3/121, IF 5.705, No. of Citations: 78)

20. Volovitz B, Tabachnik E, Nussinovitch M, Shtaif B, Blau H, Weizman A, Varsano I.
Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma.
J Allergy Clin Immunol. 1999;104(6):1162-7.
(ALLERGY Q1, 1/26, IF 13.081, No. of Citations: 53)

21. Lotem Y, Barak A, Mussaffi H, Shohat M, Wilschanski M, Sivan Y, Blau H.
Reaching the diagnosis of cystic fibrosis – limits of the spectrum.
. Israel Med Assoc J. 2000;2:94-8
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. of Citations: 7)

22. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E.
A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.
Am J Respir Crit Care Med. 2000;161:860-5.
(RESPIRATORY Q1, 2/59, IF 13.204, No. of Citations: 131)

23. Meeks M, Walne A, Spiden S, Simpson H, Mussaffi-Georgy H, Hamam HD, Fehaid EL, Cheehab M, Al-Dabbagh M, Polak Charcon S, Blau H, O'Rawe A, Mitchison HM, Gardiner RM, Chung E.
A locus for primary ciliary dyskinesia maps to chromosome 19q.
J Med Genet. 2000;37:241-4.
(GENETICS AND HEREDITY Q1 20/167, IF 5.451, No. of Citations: 52)

24. Kalina M, Blau H, Riklis S, Hoffman V.
Modulation of nitric oxide production by lung surfactant in alveolar macrophages.
Adv Exp Med Biol. 2000;479:37-48.
(MEDICINE, RESEARCH AND EXPERIMENTAL, Q3, 80/128, IF 1.937, No. of Citations: 11)

25. Augarten A, Shmilovich H, Doolman R, Aviram M, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Sela BA, Szeinberg A, Yahav Y.
Serum lipase levels as a diagnostic marker in cystic fibrosis patients .with normal or borderline sweat tests
Pediatr Pulmonol. 2000;30:320-3.
(PEDIATRICS Q1, 19/120, IF 2.758), No. of Citations: 2)

26. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E, Rivlin J, Miller MS, Katznelson D, Szeinberg A, Shmilovich H, Paret G, Laufer J, Yahav Y

MS, Katzhelson D, Szeinberg A, Shmilovich H, Paret G, Lauer J, Yahav Y.
Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients.
Pediatr Transplant. 2001;5:339-42.
(PEDIATRICS Q3, 77/121, IF 1.294, No. of Citations: 34)

27. Aravot D, Kramer M, Blau H, Berman M, Ben-Gal T, Saute M, Sagie A, Ben Dayan D, Sahar G, Eidelman L, Vidne B.
Functional status and quality of life of heart-lung transplant recipients.
Transplant Proc. 2001;33:2890-1.
(TRANSPLANTATION Q4, 23/25, IF 0.908, No. of Citations: 5)

28. Wilschansky M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H, Bentur L, Yahav Y, Springer H, Kramer MR, Klar A, Ilani A, Kerem B, Kerem E.
Nasal potential difference measurements in patients with atypical cystic fibrosis.
Eur Respir J. 2001;17:1208-15.
(RESPIRATORY SYSTEM Q1, 3/59, IF 10.569, No. of Citations: 64)

29. Vilozni D, Barker M, Jellouschek H, Heimann G, Blau H.
An interactive computer-animated system (SpiroGame) facilitates spirometry in pre-school children.
Am J Respir Crit Care Med. 2001;164:2200-5.
(RESPIRATORY Q1, 2/59, IF 13.204, No. of Citations: 74)

30. Blau H, Barak A, Karmazyn B, Ben Ari J, Mussaffi H, Schoenfeld T, Aviram M, Vinograd MD, Lotem Y, Meizner I.
Postnatal management of 'resolving' fetal lung lesions.
Pediatrics. 2001;109:105-8.
(PEDIATRICS Q1, 3/121, IF 5.705, No. of Citations: 27)

31. Blau H, Mussaffi-Georgy H, Fink G, Kaye C, Spitzer SA and Yahav J.
Effects of an Intensive 4 week summer camp on cystic fibrosis: pulmonary function, exercise tolerance and nutrition.
Chest. 2002;121:1117-22.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147, No. of Citations: 32)

32. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, Alteraz H, Kletter Y.
Immunomodulatory and Protective Effects of Moxifloxacin against Candida albicans-induced Bronchopneumonia in Mice Injected with Cyclophosphamide.
Antimicrob Agents Chemother. 2002;46:2442-9.
(MICROBIOLOGY Q1, 24/124, IF 4.302, No. of Citations: 49)

33. Blau H, Freud E, Mussaffi H, Werner M, Konen O, Rathaus V.
Urogenital abnormalities in male children with cystic fibrosis.
Arch Dis Child. 2002;87:135-8.
(PEDIATRICS Q1, 13/121, IF 3.2**65**, No. of Citations: 23)

34. Harel L, Mukamel M, Brik R, Blau H, Straussberg R.
Peripheral neuropathy in pediatric systemic lupus erythematosus.
Pediatr Neurol. 2002;27:53-6.
(PEDIATRICS Q2, 46/121, IF 2.018, No. of Citations: 30)

35. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R.
Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Eur J Pharmacol. 2003;461:27-34.
(PHARMACOLOGY AND PHARMACY, Q2, 98/257, IF 2.896, No. of

(PHARMACOLOGY AND PHARMACY, Q2, 98/207, IF 2.000, No. of Citations: 103)

36. Blau H, Livne M, Mussaffi H.
Cystic fibrosis in adults: a changing scene.
Isr Med Assoc J. 2003;5:491-5.
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. Citations: 8)

37. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E.
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
N Engl J Med. 2003;349:1433-41.
(GENERAL & INTERNAL MEDICINE, Q1, 1/155, IF 72.406, Citations: 329)

38. Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y.
Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests.
Clin Exp Med. 2003;3:119-23.
(MEDICINE, RES & EXPER Q2, 46/128, IF 2.919, No. of Citations: 4)

39. Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G, Blau H, Achdout H, de Miguel M, Gonen-Gross T, Hanna J, Arnon TI, Qimron U, Volovitz I, Eisenbach L, Blumberg RS, Porgador A, Cerundolo V, Mandelboim O.
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients.
Blood. 2004;103:1770-8.
(HEMATOLOGY Q1, 2/70, IF 13.164, No. of Citations: 51)

40. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I.
Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.
Antimicrob Agents Chemother. 2004;48:1974-82.
(MICROBIOLOGY Q1, 24/124, IF 4.302, No. of Citations: 73)

41. Markel G, Achdout H, Katz G, Ling KL, Salio M, Gruda R, Gazit R, Mizrahi S, Hanna J, Gonen-Gross T, Arnon TI, Lieberman N, Stren N, Nachmias B, Blumberg RS, Steuer G, Blau H, Cerundolo V, Mussaffi H, Mandelboim O.
Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients.
Eur J Immunol. 2004;34:2138-48.
(IMMUNOLOGY, Q2, 41/151, IF 4.227, No. of Citations:26)

42. Picard E, Aviram M, Yahav Y, Rivlin J, Blau H, Bentur L, Avital A, Villa Y, Schwartz S, Kerem B, Kerem E.
Familial concordance of phenotype and microbial variation among siblings with CF.
Pediatr Pulmonol. 2004;38:292-7.
(PEDIATRICS Q1, 19/120, IF 2.758), No. of Citations: 12)

43. Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H.
Moxifloxacin inhibits cytokine-induced MAP kinase and NF- kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line.
J Antimicrob Chemother. 2005;55:293-300.
(MICROBIOLOGY Q1, 20/124, IF 5.071, No. of Citations: 24)

44. Augarten A, Paret G, Avneri I, Akons H, Aviram M, Bentur L, Blau H, Efrati O, Szeinberg A, Barak A, Kerem E, Yahav J.

Systemic inflammatory mediators and cystic fibrosis genotype.
Clin Exp Med. 2004;4:99-102.
(MEDICINE, RESEARCH & EXPERIMENTAL Q2, 46/128, IF 2.919, No. of Citations: 11)

45. Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H.
Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy.
Eur Respir J. 2005;25:324-8.
(RESPIRATORY SYSTEM 3/59, IF 10.569, No. of Citations: 65)

46. Hanna J, Mussaffi H, Steuer G, Hanna S, Deeb M, Blau H, Arnon TI, Weizman N, Mandelboim O.
Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency.
Blood. 2005;106:3465-73.
(HEMATOLOGY Q1, 2/70, IF 13.164, No. of Citations: 20)

47. Rathaus V, Werner M, Freud E, Mei-Zahav M, Mussaffi H, Blau H.
Sonographic findings of the genital tract in boys with cystic fibrosis.
Pediatr Radiol. 2006;36:162-6.
(PEDIATRICS Q2 60/121 IF 1.611, No. of Citations: 4)

48. Mussaffi H, Prais D, Mei-Zahav M, Blau H.
Cystic fibrosis mutations with widely variable phenotype: the D1152H example.
Pediatr Pulmonol. 2006;41:250-4.
(PEDIATRICS Q1, 19/120, IF 2.758), No. of Citations: 24)

49. Falk B, Nini A, Zigel L, Yahav Y, Aviram M, Rivlin J, Bentur L, Avital A, Dotan R, Blau H.
Effect of low altitude at the Dead Sea on exercise capacity and cardiopulmonary response to exercise in cystic fibrosis patients with moderate to severe lung disease.
Pediatr Pulmonol. 2006;41:234-41.
(PEDIATRICS Q1, 19/121, IF 2.758), No. of Citations: 14)

50. Efrati O, Mei-Zahav M, Rivlin J, Kerem E, Blau H, Barak A, Bujanover Y, Augarten A, Cochavi B, Yahav Y, Modan-Moses D.
Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease.
J Pediatr Gastroenterol Nutr. 2006;42:222-8.
(PEDIATRICS Q1, 18/121, IF 2.799, No. of Citations: 34)

51. Prais D, Raviv Y, Shitrit D, Yellin A, Sahar G, Bendayan D, Yahav Y, Efrati O, Reichart N, Blau H, Bakal I, Buchman G, Saute M, Vidne B, Kramer MR.
Lung transplantation in patients with cystic fibrosis: the Israeli experience.
Isr Med Assoc J. 2006;8:396-9.
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. Citations: 2)

52. Blau H, Klein K, Shalit I, Halperin D, Fabian I.
Moxifloxacin but not ciprofloxacin o, r azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Am J Physiol. (Lung Cell Mol Physiol.) 2007;292:L343-52.
(PHYSIOLOGY Q1, 12/84, IF 4.281, No. of Citations: 40)

53. Yahav J, Samra Z, Blau H, Dinari G, Chodick G, Shmuely H.
Helicobacter pylori and Clostridium difficile in cystic fibrosis patients.
Dig Dis Sci. 2006;51:2274-9.

(GASTROENTEROLOGY AND HEPATOLOGY Q3, 39/79, IF 2.875, No. of Citations: 28)

54. Vilozni D, Bentur L, Efrati O, Minuskin T, Barak A, Szeinberg A, Blau H, Picard E, Kerem E, Yahav Y, Augarten A.
Spirometry in early childhood in cystic fibrosis patients.
Chest. 2007;131:356-61.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147, No. of Citations: 29)

55. Mussaffi H, Omer R, Prais D, Mei-Zahav M, Weiss-Kasirer T, Botzer Z, Blau H.
Computerised paediatric asthma quality of life questionnaires in routine care.
Arch Dis Child. 2007;92:678-82.
(PEDIATRICS Q1, 13/121, IF 3.265, No. of Citations: 12)

56. Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, Cohen HA.
Microbial contamination of nebulizers in the home treatment of cystic fibrosis.
Child Care Health Dev. 2007;33:491-5.
(PEDIATRICS Q2, 73/121, IF 1.445, No. of Citations 47)

57. Ben Tov A, Paret G, Sela BA, Blau H, Hegesh J, Efrati O, Yahav Y, Augarten A.
N-terminal pro B-type natriuretic peptide (N-BNP) levels in cystic fibrosis patients.
Pediatr Pulmonol. 2007;42:699-703.
(PEDIATRICS Q1, 19/120, IF 2.758) , No. of Citations: 5)

58. Yaakov Y, Kerem E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram A, Picard E, Bdolah-Abram T, Wilschanski M.
Reproducibility of nasal potential difference measurements in cystic fibrosis.
Chest. 2007;132:1219-26.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147, No. of Citations: 25)

59. Mussaffi H, Fireman EM, Mei-Zahav M, Prais D, Blau H.
Induced sputum in the very young: a new key to infection and inflammation.
Chest. 2008;133:176-82.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147, No. of Citations: 26)

60. Stanke F, Ballmann M, Bronsveld I, Dörk T, Gallati S, Laabs U, Derichs N, Ritzka M, Posselt H-G, Harms HK, Griese M, Blau H, Mastella G, Bijman J, Veeze H, Tümmler B.
Diversity of the basic defect of homozygous *CFTR* mutation genotypes .in humans
J Med Genet. 2008;45:47-54.
(GENETICS AND HEREDITY Q1, 20/167, IF 5.451, No. of Citations: 24)

61. Efrati O, Harash O, Rivlin J, Bibi H, Mei-zahav M, Blau H, Mussaffi H, Barak A,
Levy I, Vilozni D, Kerem E, Modan-Moses D.
Hemoptysis in Israeli CF patients -- prevalence, treatment and clinical characteristics.
J Cyst Fibros. 2008;7:301-6.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 18)

62. Augarten A, Ben Tov A, Madgar I, Barak A, Akons H, Laufer J, Efrati O, Aviram M, Bentur L, Blau H, Paret G, Wilschanski M, Kerem BS, Yahav J.
The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and CF genotype.

Eur J Gastroenterol Hepatol. 2008;20:164-8.
(GASTROENTEROLOGY & HEPATOLOGY Q4, 60/79, IF 1.968, No. of Citations: 35)

63. Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L, Aviram M, Rivlin J, Picard E, Lavy A, Yahav Y, Rahav G.
Multicenter cross-sectional study of nontuberculous mycobacterial infection among cystic fibrosis patients, Israel.
Emerg Infect Dis. 2008;14:378-84.
(INFECTIOUS DISEASE Q1, 3/84, IF 8.222, No. of Citations: 96)

64. Jaron R, Yaakov Y, Rivlin J, Blau H, Bentur L, Yahav Y, Kerem E, Bibi H, Picard E, Wilschanski M.
Nasal potential difference in non-classic cystic fibrosis- long term follow up.
Pediatr Pulmonol. 2008;43(6):545-9.
(PEDIATRICS Q1, 19/120, IF 2.758) , No. of Citations: 13)

65. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M.
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Lancet. 2008;372:719-27.
(MEDICINE, GENERAL & INTERNAL Q1, 2/155, IF 47.831, No. of Citations: 257)

66. Loges NT, Olbrich H, Fenske L, Mussaffi H, Horvath J, Fliegauf M, Kuhl H, Baktai G, Peterffy E, Chodhari R, Chung EM, Rutman A, O'Callaghan C, Blau H, Tiszlavicz L, Voelkel K, Witt M, Zietkiewicz E, Neesen J, Reinhardt R, Mitchison HM, Omran H.
DNA12 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm.
Am J Hum Genet. 2008;83:547-58.
(GENETICS & HEREDITY Q1, 8/167, IF 9.025, No. of Citations 115)

67. Segal I, Yaakov Y, Adler SN, Blau H, Broide E, Sanot M, Yahav Y, Klar A, Lerner A, Aviram M, Ellis I, Mountford R, Shteyer E, Kerem E, Wilschanski M.
Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis.
J Clin Gastroenterol. 2008;42:810-4.
(GASTROENTEROLOGY & HEPATOLOGY Q2, 31/79, IF 3.328, No. of Citations 15)

68. Weintraub A, Blau H, Mussaffi H, Picard E, Bentur L, Kerem E, Stankiewicz H, Wilschanski M.
Exocrine Pancreatic Function Testing in Patients with CF and Pancreatic Sufficiency: A Correlation Study.
J Pediatr Gastroenterol Nutr. 2009;48:306-10.
(PEDIATRICS Q1, 18/121, IF 2.799, No. of Citations 26)

69. Bar-Yishay E, Matyashchuk E, Mussaffi H, Mei-Zahav M, Prais D, Hananya S, Steuer G, Blau H.
Use of the forced oscillation technique to detect bronchodilation in children: experience from Schneider Children's Medical Center of Israel.
Isr Med Assoc J. 2009;11:198-200.
(MEDICINE, GENERAL & INTERNAL Q3, 98/155, IF 1.036, No. of Citations 4)

70. Schneebaum N*, Blau H*, Soferman R, Mussaffi H, Ben-Sira L, Schwarz M,

Sivan Y. [*Equal contribution]
Use and yield of chest computed tomography in the diagnostic evaluation of pediatric lung disease.
Pediatrics. 2009;124:472-9.
(PEDIATRICS Q1, 3/121, IF 5.705, No. of Citations 8)

71. Cohen-Cymerknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E.
Intravenous monthly pulse methylprednisolone therapy vs oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis.
J Cyst Fibros. 2009;8:253-7.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 0)

72. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, Donnelly K, Elfring GL, Ajayi T, Kerem E.
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 38:59-69; 2011.
Erratum in: Eur Respir J. 2011 Oct;38:996. Pugatch, T [corrected to Pugatsch, T].
(RESPIRATORY SYSTEM Q1, 3/59, IF 10.569, No. of Citations 105)

73. Kerem E, Wilschanski M, Miller NL, Pugatsch T, Cohen T, Blau H, Rivlin J, Shoseyov D, Reha A, Constantine S, Ajayi T, Hirawat S, Elfring GL, Peltz SW, Miller LL.
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis.
J Cyst Fibros. 2011;10:193-200.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 2

74. Mitchison HM, Schmidts M, Loges NT, Freshour J, Dritsoula A, Hirst RA, O'Callaghan C, Blau H, Al Dabbagh M, Olbrich H, Beales PL, Yagi T, Mussaffi H, Chung EM, Omran H, Mitchell DR.
Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia.
Nat Genet. 2012;44:381-9.
(GENETICS & HEREDITY Q1, 2/167, IF 40.282, No. of Citations 81)

75. Kaplan E, Yishay EB, Prais D, Klinger G, Zahav MM, Mussaffi H, Steuer G, Hananya S, Matyashuk Y, Gabarra N, Sirota L, Blau H.
Encouraging pulmonary outcome for surviving, neurologically intact extremely premature infants in the post surfactant era.
Chest. 2012;142:725-33.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147; No. of Citations 31)

76. Ciro D, Padoan R, Blau H, Marostica A, Fuoti M, Volpi S, Pilotta A, Meyerovitch J, Sher D, Assael BM.
Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers.
J Cyst Fibros. 2013;12:165-9.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 5)

77. Blau H, Linnane B, Carzino R, Tannenbaum E-L, Skoric B, Robinson P, Robertson C, Ranganathan S.
Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.
J Cyst Fibros. 2014;13:106-10.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 0)

78. Peled O, Kalamaro V, Kerem E, Shoseyov D, Blau H, Efrati O, Block C.
Contamination of hypertonic saline solutions in use by cystic fibrosis patients in Israel.
J Cyst Fibros. 2014;13:550-6.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 2)

79. Prais D, Sinik MM, Stein J, Mei-Zahav M, Mussaffi H, Steuer G, Hananya S,
Krauss A, Yaniv I, Blau H.
Effectiveness of long-term routine pulmonary function surveillance following pediatric hematopoietic stem cell transplantation.
Pediatr Pulmonol. 2014;49:1124-32.
(PEDIATRICS Q1, 19/120, IF 2.758) , No. of Citations 0)

80. Cohen HA*, Blau H*, Hoshen M, Batat E, Balicer RD. [*equal first authors]
Seasonality of asthma: a retrospective population study.
Pediatrics. 2014;133:e923-32.
(PEDIATRICS Q1, 3/121, IF 5.705, No. of Citations 11)

81. Bar-On O, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Stafler P, Hananya S,
Blau H.
Increasing nontuberculous mycobacteria infection in cystic fibrosis.
J Cyst Fibros. 2015;14:53-62.
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 37)

82. Amirav I, Mussaffi H, Roth Y, Schmidts M, Omran H, Werner C; Israeli PCD Consortium Investigators (Abitbul R, Alkrinawi S, Aviram M, Avital A, Baso D, Bentur L, Blau H, Cohen-Cymberknoh M, Dabbah H, Elias N, Elizur A, Goldberg S, Hevroni A, Kerem E, Lavie M, Livnat G, Luder A, Mandelberg A, Paz M, Picard E, Rivlin J, Rotschild , Shoseyov D, Soferman R, Springer C, Raidt J.
A reach-out system for video microscopy analysis of ciliary motions aiding PCD diagnosis.
BMC Res Notes. 2015;8:71;1-7.
(No IF, No. of Citations 6)

83. Mei-Zahav M, Livnat G, Bentur L, Mussaffi H, Prais D, Stafler P, Bar-On O, Steuer G, Blau H.
The Spectrum of Nocardia Lung Disease in Cystic Fibrosis.
Pediatr Infect Dis J. 2015;34:909-11.
(PEDIATRICS Q1, 27/121, IF 2.486, No. of Citations 1)

84. Prais D, Kaplan E, Klinger G, Mussaffi H, Mei-Zahav M, Bar-Yishay E, Stafler P, Steuer G, Sirota L, Blau H.
Short- and Long-Term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.
Chest. 2016 Mar;149:801-8.
(RESPIRATORY SYSTEM Q1, 7/59, IF 6.147, No. of Citations 4)

85. Stafler P, Mei-Zahav M, Wilschanski M, Mussaffi H, Efrati O, Lavie M, Shoseyov D, Cohen-Cymberknoh M, Gur M, Bentur L, Livnat G, Aviram M, Alkrinawi S, Picard E, Prais D, Steuer G, Inbar O, Kerem E, Blau H.
The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening.
J Cyst Fibros. 2016 July; 15:460-466
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 3)

86. Mussaffi H, Shvalb NF, Ben-Zvi H, Livni G, Mei-Zahav M, Prais D, Stafler P

86. Mussaffi H, Shvalb NF, Ben-Zvi H, Livni G, Mei-Zahav M, Prais D, Stafler P, Steuer G, Blau H.
Clinical Impact of Beta-Lactamase Producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients.
Pediatr Infect Dis J. 2016 Feb;35:216-9
(PEDIATRICS Q1, 27/121, IF 2.486, No. of Citations: 1)

87. Levine H, Cohen-Cymberknoh M, Klein N, Hoshen M, Mussaffi H, Stafler P, Breuer O, Kerem E and Blau H.
Reversible airway obstruction in cystic fibrosis: common, but not associated with characteristics of asthma.
J Cyst Fibros. 2016 Sep;15:652-9
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 2)

88. Cohen HA, Hoshen M, Gur S, Bahir A, Laks Y and Blau H.
Efficacy and tolerability of a polysaccharide-resin- honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded, multicenter study.
World J Pediatr, 2017 Feb;13(1):27-33
(PEDIATRICS Q3, 88/120, IF 1.025, No. of Citations: 0)

89. Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, Rivlin J, Gur M, Shteinberg M, Bentur L, Livnat G, Aviram M, Picard E, Tenenbaum A, Armoni S, Breuer O, Shoseyov D and Kerem E.
Eradication failure of newly acquired *Pseudomonas aeruginosa* isolates in cystic fibrosis
J of Cyst Fibros 2016 Nov;15:776-782
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 5)

90. Abitbul R, Amirav I, Blau H, Alkrinawi S, Aviram M, Shoseyov D, Bentur L, Avital A, Springer C, Lavie M. Prais D, Dabbah H, Elias N, Elizur A, GOldber S, Kerem E, Luder A, Roth Y, Cohen-Cymberknoh M, Ben Ami M, Mandelberg A, Livnat G Picard E, Rivlin J, Rotschild M, SOferman R, Loges NT, Olbrich H, Werner C, Wolter A, Herting M, Wallmeier J, Raidt J, Omran H, Mussaffi H.
Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practices
Respir Med 2016 Oct;119:41-47
(RESPIRATORY SYSTEM Q2, 19/59, IF 3.217, No. of Citations: 2)

91. Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA.
Diagnosis of cystic fibrosis in screened populations
J Pediatr 2017: 181S: S33-44
(PEDIATRICS Q1, 7/121, IF 3.874. No. of citations: 9)

92. Stafler PS, Weinreb S, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Bar-On O, Hoshen M, Blau H
Feasibility of multiple breath washout measurements in infants with bronchiolitis: A pilot study
Pediatr Pulmonol 2017 Jun: 52:763-770
(PEDIATRICS Q1, 19/120, IF 2.758. No. of citations: 1)

93. Behar DM, Inbar O, Shteinberg M, Gur M, Mussaffi H, Shoseyov D, Ashkenazi M, Alkrinawi S, Bormans CA, Hakim F, Mei-Zahav M, Cohen-Cymberknoh M, Dagan A, Prais D, Sarouk Y, Stafler P, Bar Aluma BE, Akler G, Picard E, Aviram M, Efrati O, Livnat G, Rivlin J, Bentur L, Blau H, Kerem E, Singer A
Nation-wide genetic analysis for molecularly unresolved cystic fibrosis patients in a multi-ethnic society: Implications for preconception carrier screening
Mol Genet Genomic Med 2017 Feb; 5:223-236
(GENETICS AND HEREDITY Q2, 69/167, IF 2.979, No. citations: 0)

(GENETICS AND HEREDITY Q2, 33/107, IF 2.570, No. of citations: 0)

94. Mei-Zahav M, Blau H, Hoshen M, Zvulunov A, Mussaffi H, Prais D, Stafler P, Steuer G, Lapidoth M, Amitai DB.
Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing.
Pediatr Pulmonol. 2017 Aug; 52:1071-1075
(PEDIATRICS Q1, 19/120, IF 2.758, No. of Citations:0)

95. Levine H, Prais D, Raviv Y, Rusanov V, Rosengarten D, Saute M, Hoshen M, Mussaffi H, Blau H, Kramer MR.
Lung transplantation in cystic fibrosis patients in Israel: The importance of ethnicity and nutritional status.
Clin Transplant. 2017 Nov;31(11)
(TRANSPLANTATION Q3, 8/25, IF 1.865, No. of Citations:0)

96. Dagan A, Cohen-Cymberknoh M, Shteinberg M, Levine H, Vilozni D, Bezalel Y, Bar Aluma BE, Sarouk I, Ashkenazi M, Lavie M, Tsabari R, Blau H, Kerem E, Bentur L, Efrati O, Livnat G.
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
Respir Med. 2017 Oct;131:225-228
(RESPIRATORY SYSTEM Q2, 19/59, IF 3.217, No. of Citations: 0)

97. Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A, Breuer O, Simanovsky N, Boon M, De Boeck K, Barbato A, Snijders D, Collura M, Pradal U, Blau H, Mussaffi H, Price M, Bentur L, Gur M, Aviram M, Picard E, Shteinberg M, Livnat G, Rivlin J, Hiller N, Shoseyov D, Amirav I, Kerem E.
Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia.
Respir Med. 2017 Oct;131:241-246
(RESPIRATORY SYSTEM Q2, 19/59, IF 3.217, No. of Citations: 0)

98. Mei-Zahav M, Blau H, Bruckheimer E, Zur E, Goldschmidt N.
Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia – a preliminary report
J Otolaryngol Head Neck Surg. 2017 Oct; 46:58
(OTORHINOLARYNGOLOGY Q2, 20/42, IF 1.495, No. of Citations: 1)

99. Cohen-Cymberknoh M, Tanny T, Breuer O, Blau H, Mussaffi H, Kadosh D, Gartner S, Salinas A, Bentur L, Nir V, Gur M, Reiter J, Shoseyov D, Kerem E, Berger I.
Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis.
J Cyst Fibros. 2018 Mar;17(2):281-285
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 0

100. G Steuer, P Stafler, H Mussaffi, M Mei-Zahav, O Bar-On, Y Gendler, H Blau, D Prais
Inspiromatic- Safety and Efficacy Study of a New Generation Dry Powder Inhaler in Asthmatic Children.
Pediatr Pulmonol 2018 Oct;53:1348-1355
(PEDIATRICS Q1, 19/120, IF 2.758, No. of Citations:0)

101. M Shteinberg, AB Lulu, DG Downey, Z Blumenfeld, C Rousset-Jablonski, M Perceval, A Colombo, N Stein, G Livnat, M Gur, L Bentur, H Mussaffi, **H Blau**, I Sarouk, A Dagan, E Kerem, M Aviram, E Picard, S Aliberti, A Álvarez, J Perez-Miranda, E Polverino, I Durieu, SJ Elborn, M Cohen-Cymberknoh
Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age.
J Cyst Fibros. 2019 Jul;18(4):525-529
(RESPIRATORY SYSTEM Q1, 8/59, IF 4.727, No. of Citations: 0

102. M Mei-Zahav, P Stafler, H Senderowitz, L Bentur, G Livnat, M Shteinberg, N Orenstein, L Bazak, D Prais, H Levine, M Gur, N Khazanov, L Simhaev, H Eliyahu, M Cohen, M Wilschanski, **H Blau**, H Mussaffi.
The Q359K/T360K mutation causes cystic fibrosis in Georgian Jews.
J Cyst Fibros. 2018 Sep;17(5):e41-e45. [Epub ahead of print]

103. Levine H, Leventer-Roberts M, Hoshen M, Mei-Zahav M, Balicer R, Blau H
Healthcare utilization in infants and toddlers with asthma-like symptoms.
Pediatr Pulmonol. 2019 Oct;54(10):1567-1577
(PEDIATRICS Q1, 19/120, IF 2.758, No. of Citations:0)

B.2. CASE REPORTS published

1. Shalev J, Itzchak Y, Blau H, Rosenman J, Ben Refael Z, Brish M, Mashiach S,
Serr DM.
The prenatal ultrasonic diagnosis of urethral obstruction and diverticulum of the urinary bladder.
Pediatr Radiol. 1982;12:48-50.

2. Yancu Y, Szeinberg A, Rosenman Y, Blau H, Zack J, Yahav J.
Pneumothorax in cystic fibrosis: intrapleural instillation of Atabrine.
Harefuah. 1991;120:264-6.

3. Aravot D, Kramer M, Blau H, Dagan O, Eidelman L, Vidne B.
First successful heart-lung transplantation for cystic fibrosis in Israel.
Transplant Proc. 1999;31:1875-7.

4. Mussaffi H, Greif J, Kornreich L, Ashkenazi S, Levy Y, Schonfeld T, Blau H.
Severe allergic bronchopulmonary aspergillosis in an infant with cystic fibrosis and her asthmatic father.
Pediatr Pulmonol. 2000;29:155-9.

5. Fink G, Lebzelter J, Blau C, Klainman E, Aravot D, Kramer MR.
The sky is the limit: exercise capacity 10 years post-heart-lung transplantation.
Transplant Proc. 2000;32(4):733-4.

6. Nofech-Mozes Y, Schoenfeld T, Blau H, Kornreich L, Ashkenazi S.
Seizures, severe encephalopathy and brain edema caused by Shigella Sonnei infection in Cystic Fibrosis.
Pediatr Int. 2000;15:162-5.

7. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D.
Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.
Ophthalmology. 2006;113:1184-6.

C. CHAPTERS IN BOOKS

1. Guzowski D, Blau H, Bienkowski RS.
The role of extracellular matrix in developing lung.
In: Pulmonary Physiology of the Fetus, Newborn, Child and Adolescent.
Editor: EM Scarpelli.
Lea and Febiger, Philadelphia, USA, 1989.

INVITED PAPERS IN SCIENTIFIC MEETINGS

1. Blau H
   Invited to head the Medical-Scientific Committee for the 12th International conference of Cystic Fibrosis, Jerusalem, 1996 (held once in 4 years) and thus
   to select 40 international key-note speakers, as well as presentations in workshops, symposia, poster discussions.

2. Blau H.
   Organized and participated in a panel discussion on the "doctor-patient relationship in cystic fibrosis" at the 12th International Conference of Cystic Fibrosis, Jerusalem, Israel, 1996.

3. Blau H.
   Organized and chaired a workshop on pulmonary disease at the International Conference on Adolescent Medicine, Jerusalem, Israel, September 2000.
   a. Invited presentation on: Issues and challenges in adolescent asthma
   b. Invited presentation on: The adolescent with cystic fibrosis- coping strategies
   c. Invited to participate in panel discussion on: The adolescent with chronic disease

4. Blau H.
   Invited organizer and chairperson of nurses' workshop and conference as part of the International Conference on Aerosols in Medicine.
   Keynote speaker: Inhalations in Medicine: State of the Art, Tel Aviv, Israel, June 2000.

5. Blau H.
   "Meet the Professor" seminar for 1 hour on: Non-tuberculous mycobacteria in cystic fibrosis: diagnostics, significance and management, The European Cystic Fibrosis Conference, Vienna, Austria, June 2001.

6. Blau H.
   Invited chairman of a Workshop on Unusual Presentations of CF, and presented a keynote lecture on : CF- the limits of the spectrum, at the European Cystic Fibrosis Conference, Vienna, Austria, June 2001.

7. Blau H.
   Invited lecture to the Australian Jewish Medical Federation, Malvern, Melbourne, Australia. July 2006. Cystic fibrosis: a model for care of the chronically ill child.

8. Blau H.
   Invited to give the key-note address on Cystic Fibrosis at the investigators meeting for the multinational multicenter study on a new inhaler device for Tobramycin inhaled powder. Rome, Italy, October 2007.

9. Blau H.
   Invited to participate in European Research Society Research Seminar on "Preparing for the first early pulmonary intervention studies in infants and preschool children with Cystic Fibrosis" in Rotterdam, Holland, February 2012.

Included a group of about 50 CF leaders internationally to decide on early outcome measures for future research trials. My area of specialty: Induced sputum in young, non-expectorating children, was later adapted as Standard of Practice for the European CF Society

10. Blau H.
    Emerging infections in cystic fibrosis.

The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October 2012.

11. Blau H.
Cystic fibrosis as a management model for chronic respiratory diseases. Symposium. The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October 2012.

12. Blau H.
The changing face of the cystic fibrosis clinic.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October 2012.

13. Blau H.
Pulmonary function in children born with extreme prematurity. Plenary session.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October 2012.

14. Blau H
Induced Sputum in non-expectorating young children
Standard Operating Procedures (SOP) of the European Cystic Fibrosis Society (ECFS), Lisbon, Portugal, June 2013.

15. Blau H
Induced sputum in the first two years of life
Consensus Conference on Diagnosis in Cystic Fibrosis
North American Cystic Fibrosis Conference (NACFC), Phoenix, AZ, .USA, October 2015

16. Blau H
Cystic fibrosis: current and long term safety data with innovative and future treatments
LEAD CF International Meeting, Jerusalem, December 2016

17. Blau H
Barriers to Newborn Screening for CF: Israel
ECFS Neonatal screening working group annual meeting
ECFS conference, Seville, Spain, June 2017

PAPERS PRESENTED AT SCIENTIFIC MEETINGS PUBLISHED AS ABSTRACTS

1. Blau H, Guzowski D, Bienkowski RS, Scarpeilli EM.
Ambroxol stimulates lipid synthesis nonspecifically in rabbit fetal lung fibroblasts and type 2 cells.
Clin Res. 34:574A, 1986.

2. Blau H, Guzowski D, Scarpelli EM, Bienkowski R.
Alveolar-like structures form in long term cultures of type 2 cells on gel matrix.

Clin Res. 34:883A, 1986.

3. Blau H, Guzowski D, Scarpelli E, Bienkowski R.
Fetal type 2 pneumocytes form alveolar-like structures and maintain long term function on extracellular matrix.
Pediatr Res. 21(4) pt2:500A, 1987.

4. Blau H, Guzowski D, Bienkowski RS, Scarpelli EM

4. Blau H, Gdzowski D, Bienkowski RS, Scarpelli EM.
Lipid protein metabolism in fetal type 2 pneumocytes and lung fibroblasts: Ambroxol effects.
Pediatr Res. 21(4) pt2:444 A 1987.

5. Olson A, Blau H, Danna D, Bienkowski R, Davidson M.
Regulation of Intestinal epithelial cell attachment and growth by extracellular matrix (ECM).

D.3. PAPERS PRESENTED AT SCIENTIFIC MEETINGS PUBLISHED AS ABSTRACTS (cont)

Pediatr Res. 21(4) pt2:274, A ,1987.

6. Antonio-Santiago MT, Blau H, Desjeunes D, Jacobson MS, et al.
Pulmonary function tests in anorexia nervosa patients.
Pediatr Res. 23(4)pt2:201 A. ,1988.

7. Blau H, Fink TG, Kay C, Shonfeld T, Yahav Y, Spitzer S.
Effects of an intensive 4 week program on lung function and exercise tolerance in CF.
5th Annual North American CF Conference.
Pediatr Pulmonol. Suppl. 6; p. 231,1991.

8. Kalina M, Riklis S, Blau H.
Alveolar type II cell-like cells; a sub-population of alveolar type II cells that concomitantly maintain proliferation and aspects of surfactant synthesis in long term culture.
American Thoracic Society Meeting, Anaheim, CA, USA, May 1991.
Am Rev Resp Dis. 143 (4) pt 2:A302, 1991.

9. Blau H, Riklis S, Kalina M.
Type II alveolar epithelial cells secrete colony stimulating factors including GMCSF in short and long term cultures.
American Thoracic Society Meeting, Miami Beach, Florida, USA, May 1992.
Am Rev Resp Dis. 145(4) pt 2:A138, 1992.

10. Blau H, Kravtsov C, Riklis S, Kalina M.
Surfactant Protein A (SPA) binds to bacterial LPS with inhibition of SPA-mediated CSF secretion and phagocytosis by alveolar macrophages.
American Thoracic Society Meeting, Boston, MA, USA, May 1994.
Am Rev Resp Dis. April, 1994.

11. Kerem E, Yahav Y, Rivlin Y, Blau H, Aviram M, Bentur L, et al.
Comparison of phenotypes of CF patients carrying the same genotype from different ethnic origins.
10th Annual North American Cystic Fibrosis Conference, Orlando, FL, USA, October 1996.
Pediatr Pulmonol. S13, 138-139, 1996.

12. Blau H, Rudeberg A, Lang A, Heijerman H.
Long term intravenous immune globulin therapy resulting in dramatic, sustained improvement of severe CF lung disease.
12th International Cystic Fibrosis Conference, Jerusalem, Israel, June 1996.
Isr J Med Sci. 32:S172, 1996.

13. Cohen S, Yahav Y, Rivlin Y, Blau H, Aviram M, Springer C, Bentur L, Augarten A, Szeinberg A, Tal A, Picard E, Wilshanski M, Abelyovich D, Branski D, Kerem B, Kerem E.
Association of liver disease and “severe” CFTR genotype in cystic fibrosis.
12th International CF Conference, Jerusalem, Israel, June 1996.

Isr J Med Sci. 32:S251, June 1996.

14. Cohen S, Yahav Y, Wilschanski M, Rivlin J, Blau H, Aviram M, Bentur L, Augarten A, Springer C, Szeinberg A, Tal A, Branski D, Kerem B, Kerem E.
Clinical and genetic risk factors for the development of liver disease in CF.
10th Annual North American Cystic Fibrosis Conference, Orlando, FL, USA, October 1996.
Pediatr Pulmonol. S13:246-7, 1996.

15. Kalina M, Riklis S, Blau H.
Surfactant protein A and lipids modulate nitric oxide production by alveolar macrophages.
American Thoracic Society Conference, San Francisco, CA, USA, May 1997.
Am J Resp Crit Care Med. 155:4 (part 2), A215, 1997

16. Kalina M, Hoffman V, Riklis S, Blau H.
Surfactant lipids and proteins A and D modulate nitric oxide generation by alveolar macrophages.
American Thoracic Society, Chicago, USA, Arpil 1998.
Am J Resp Crit Care Med .157:3, A557, 1998

17. Blau H, Ronen I, Mussaffi H, Yinon A.
Effect of the mother's coping style and the child's temperament on adherence to therapy and disease control in childhood asthma.
American Thoracic Society, Chicago, USA, Arpil 1998.
Am J Resp Crit Care Med. 157:3, A737, 1998.

18. Kerem E, Famini C, Aviram M, Blau H, et al.
Nasal potential difference measurements in patients with atypical CF disease.
12th Annual North American CF Conference, Montreal, Canada, October 1998.
Pediatr Pulmonol. S17: 251, 1998.

19. Wilschanski M, Famini C, Blau H, et al.
Topical gentamicin rectifies abnormal nasal potential difference measurements in CF patients homozygous for stop mutations.
12th Annual North American CF Conference, Montreal, Canada, October 1998.
Pediatr Pulmonol. S17: 253, 1998.

20. Vilozni D, Blau H, Merklein R, et al.
A unique animated interactive spirometer (CAIS) to enable pulmonary function testing in pre-school children.
American Lung Society/American Thoracic Society Conference, San Diego, USA, April 1999.
. Am J Resp Crit Care Med. Suppl. A672, 1999

21. Barak A, Karmazyn B, Meizner I, Ben-Ari J, Mussaffi H, Schoenfeld T, Aviram M, Lotem Y, Blau H.
The role of chest computerized tomography in the postnatal evaluation of prenatally diagnosed congenital lung lesions.
European Respiratory Society Annual Congress, Madrid, Spain, October 1999.
Eur Resp J. 14: S30, p 499S, 1999.

22. Meeks M, Walne A, Spiden SI, Blau H, Mussaffi-Georgy H, Simpson H, El Fehaid M, Cheehab M, Al-Dabbagh M, Hammum HD, Gardiner RM, Chung EMK, Meeks M.
Identification of a locus for primary ciliary dyskinesia (PCD; Kartagener syndrome) on chromosome 19.
American Society of Human Genetics Annual Meeting, San Francisco, CA, USA, October 1999.

Am J Hum Genet. 65 (S4) p A31, 1999.

23. Kerem E, Famini C, Blau H, et al.
Topical gentamicin rectifies abnormal nasal PD measurements in CF patients carrying stop mutations.
23rd European CF Conference, The Hague, The Netherlands, June 1999.
Neth J Med. 54: S3-S84, p S84, 1999.

24. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Shmulovich H.
Prediction of mortality and timing of lung transplantation in CF patients. 13th Annual North American CF Conference, Seattle, Washington, USA, October 1999.
Pediatr Pulmonol. S19, p 292, 1999.

25. Augarten A, Berman H, Aviram M, Bentur L, Blau H, Kerem E, Rivlin J, Akons H, Szeinberg A, Yahav Y.
Serum CA 19-9 levels as a diagnostic marker in CF patients with normal or borderline sweat tests.
14th Annual North American CF Conference, Baltimore, Maryland, USA, November 2000.
Pediatr Pulmonol. S20: 214, 2000.

26. Weisberg H, Foldesh Y, Aviram M, Ben-Tur L, Blau H, Picard E, Goldberg S,
Virgilis D, Kerem E.
Similar rates of osteoporosis in CF patients with pancreatic insufficiency and pancreatic sufficiency.
14th Annual North American CF Conference, Baltimore, Maryland, USA, November 2000.
Pediatr Pulmonol. Suppl. 20, p 322, 2000

27. Wilschanski M, Yahav Y, Blau H, Bentur L, Tal A, Strauss-Liviatan N, Virgilis D, Famini H, Kerem B, Kerem E.
Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: a double-blind placebo controlled trial.
14th Annual North American CF Conference, Baltimore, Maryland, USA, November 2000.
Pediatr Pulmonol Suppl. 20, p 244, 2000.

28. Blau H, Werner M, Mussaffi H, Freud E, Konen O, Livne M, Rathaus V.
Heterogeneity of tract abnormalities in male children with cystic fibrosis (CF): correlation with disease severity.
15th Annual North American CF Conference, Orlando, FL, USA, October 2001.
Pediatr Pulmonol Suppl. 22, p 190, 2001.

29. Wilschanski M, Winchester T, Bentur L, Blau H, Rivlin J, Bibi H, Yahav Y, Aviram M, Goldberg S, Picard E, Kerem B, Kerem E.
Variable nasal potential difference measurements in individuals carrying the 5T allele.
15th Annual North American CF Conference, Orlando, FL, USA, October 2001.
Pediatr Pulmonol Suppl. 22, p 214, 2001

30. Picard E, Yahav Y, Rivlin J, Blau H, Bentur L, Aviram M, Springer C, Mayevski H, Kerem B, Kerem E.
Cystic fibrosis in siblings: potential role of modifier genes and cross-infection.
15th Annual North American CF Conference, Orlando, FL, USA, October 2001.
Pediatr Pulmonol Suppl. 22, p 222, 2001.

31. Vilozni D, Barak A, Blau H, Efrati O, Mussaffi H, Szeinberg A, Augarten A,

Yahav Y.
Flow volume loops in 2-6 year old children with CF using a spirogame.
15th Annual North American CF Conference, Orlando, FL, USA, October 2001.
Pediatr Pulmonol Suppl. 22, p 315, 2001.

32. Blau H, Fabian I, Kletter Y, Horev L, Kariv N, Shechtman I, Alteraz H.
Protective immunomodulation by moxifloxacin against Candida albicans lung infection in cyclophosphamide treated mice: suppression of TNF□, IL-8 and NF kappa B activation.
American Thoracic Society Annual Congress, Atlanta, Georgia, USA, May 2002.
Am J Resp Crit Care Med. 165(8):A782, 2002.

33. Wilschanski M, Yahav Y, Blau H, Bibi H, Weisman N, Arnon R, Klar A, Broide E, Kerem E.
The use of nasal potential difference measurements in recurrent pancreatitis.
25th European Cystic Fibrosis Meeting, Genoa, Italy, June 2002.
J Cystic Fibros. 1:S65, 2002.

34. Augarten A, Paret G, Avneri I, Akons H, Aviram M, Bentur L, Blau H, Kerem E, Efrati O, Szeinberg A, Barak A, Yahav J.
The linkage between serum chemokines, pulmonary function and CF genotype.
16th Annual North American Cystic Fibrosis Conference, New Orleans, LA, USA, October 2002.
Pediatr Pulmonol. 2002;34:S24 p 271, A267.

35. Blau H.,Eliakim A, Mussaffi H, Barak A, Yahav Y, Bentur L, Kerem E, Rivlin J, Aviram M, Springer C, Zigel L, Epstein M, Constantini N, Falk B.
An individualized exercise program with personal trainer for sedentary Israeli CF children: Effects on lung function, respiratory reserve, serum IL-8 and leptins.
17th Annual North American CF Conference, Anaheim, CA, USA, October 2003.
Pediatr Pulmonol Suppl. 2003;25:328.

36. Cohen A, Mussaffi H, Livne M, Blau H.
Microbial contamination of nebulizers in home treatment of cystic fibrosis patients.
17th Annual North American CF Conference, Anaheim, CA, USA, October 2003.
Pediatr Pulmonol 2003;Suppl 25: 328.

37. Shushi L, Nissim-Rafinia M, Natan C, Kerem E, Wilschanksi M, Yaakov Y, Rivlin J, Yahav Y, Blau H, Bentur L, Kerem B.
NMD pathway regulates the response to aminoglycoside treatment.
18th Annual North American Cystic Fibrosis Conference, St Louis, Missouri, USA, October 2004; Symposium S17.4.
Pediatr Pulmonol. 2004; 38 S27:175.

38. Wilschanski M, Segal I, Yaakov Y, Adler S, Broide E, Blau H, Schildkraut V, Bibi H, Arnon R, Klar A, Vaisman N, Koler O, Yahav Y, Arad-Cohen N, Santo M, Kerem E.
The use of nasal potential difference measurements in recurrent pancreatitis.
18th Annual North American Cystic Fibrosis Conference, St Louis, Missouri, USA, October 2004.
Pediatr Pulmonol. 2004; 38 S27:212.

39. Barak A, Yahav J, Aviram M, Efrati O, Bentur L, Blau H, Wilschanski M, Kerem E, Augarten A.

Pancreatitis, pancreatic function and cystic fibrosis.
18th Annual North American Cystic Fibrosis Conference, St Louis, Missouri, USA, October 2004
Pediatr Pulmonol. 2004;38 S27:334.

40. Blau H, Wieser K, Shalit I, Halperin D, Fabian I.
Moxifloxacin but not ciprofloxacin markedly inhibits secretion of IL-8 by a CF bronchial epithelial cell line (IB3).
American Thoracic Society 2005 International Conference, San Diego, CA, USA, May 2005.
Am J Respir Crit Care. 2005, Supplement A

41. Yaacov Y, Kerem E, Yahav Y, Blau H, Rivlin J, Bentur L, Picard E, Aviram M, Wilschanski M.
Reproducibility of nasal potential difference measurements in CF.
28th European CF Conference, Hersonissos, Crete, Greece, June 2005.

42. Mussaffi H, Fireman E, Mei-Zahav M, Monselise Y, Prais D, Blau H.
Induced sputum in infants and non-expectorant children with Cystic Fibrosis is safe and beneficial.
19th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 2005.
Pediatr Pulmonol Suppl. 2005;28:312.

43. Mussaffi H, Omer R, Mei-Zahav M, Weiss- Kasirer T, Botzer Z, Prais D, Blau H.
Contribution of electronic version of the pediatric asthma quality of life Questionnaires in routine asthma care.
American Thoracic Society 2006 International Conference, San Diego, CA, USA, May 2006.
Am J Resp Critical Care Med. 2006;Suppl A594.

44. Kerem E, Hirawat S, Armoni S, Yaacov Y, Blau H, Rivlin J, Aviram M, Shoseyov D, Cohen M, Northcutt VJ, Elfring GL, Miller L, Wilschanski M.
PTC24 activity in CF patients carrying stop mutations: interim results of a phase 2 study.
20th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2006.
Pediatr Pulmonol. 2006;41 S29:291.

45. Vilozni D, Bentur L, Efrati O, Minuskin T, Barak A, Szeinberg A, Blau H, Picard E, Kerem E, Yahav Y, Augarten A.
Spirometry in preschool children with cystic fibrosis.
20th Annual North American Cystic Fibrosis Conference, Denver, Colorado, USA, November 2006.
Pediatr Pulmonol. 2006;41 S29:347.

46. Mei-Zahav M, Freud N, Mussaffi H, Prais D, Blau H.
Cardiopulmonary assessment of children with pectus excavatum before and after nuss procedure. American Thoracic Society Annual International Congress, San Francisco, CA, USA, May 2007.
Am J Resp Crit Care Med. 2007;175 Suppl. A862.

47. Gur M, Bardin R, Mussaffi H, Schonfeld T, Mei-Zahav M, Prais D, Meisner I, Blau H.
Long term follow up of prenatally diagnosed congenital lung lesions.
American Thoracic Society Annual Conference, Toronto, Ontario, Canada, May 2008.

48. Sivan Y, Schneibaum N, Soferman R, Mussaffi H, Ben-Sira L, Schwarz M, Ben-Ari J, H. Blau

Ben-Ari J, H. Blau.
Yield of chest CT scan in the evaluation of pediatric lung diseases.
American Thoracic Society Annual Conference, Toronto, Ontario, Canada, May 2008.

49. Kerem E, Yaakov Y, Armoni S, Pugatsch T, Shoseyov D, Cohen M,
Blau H,
Hirawat S, Reha A, Elfring G, Miller L, Wilschanski M.
PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis.
22nd Annual North American Cystic Fibrosis Conference, Orlando, FL, USA, October 2008.
Pediatr Pulmonol. 2008;43 S31:294-5.

50. Mantin H, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Taizi T, Rosenfeld S, Blau H.
Use of the intrapulmonary percussive ventilator (IPV) in an Israeli CF clinic.
22nd Annual North American Cystic Fibrosis Conference, Orlando, FL, USA, October 2008.
Pediatr Pulmonol. 2008;43 S31:395.

51. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E.
Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary Aspergillosis in cystic fibrosis.
American Thoracic Society International Conference, San Diego, CA, USA, May 2009; A1184.

52. Prais D, Marx-Sinik M, Stein J, Bar-Yishay E, Mussafi H, Mei-Zahav M, Steuer G, Yaniv I, Blau H.
Long-term pulmonary function following bone marrow transplantation in pediatric patients.
American Thoracic Society International Conference, New Orleans, Louisiana, USA, May 2010; A6730.

53. Prais D, Peleg-Weiss L, Mussaffi H, Mei-Zahav M, Steuer G, Blau H.
The role of quantitative ultrasound in the evaluation of CF related bone status.
24th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 2010.

54. Bar-Yishay E, Matyashchuk E, Mussaffi H, Prais D, Steuer G, Mei-Zahav M, Hanahya S, Blau H.
fractional exhaled nitric oxide does not correlate with functional measures in pre-school wheezy children.
American Thoracic Society International Conference, New Orleans, Louisiana, USA, May 2010.
Am J Respir Crit Care Med. 2010;181:A3922.

55. Bar-Yishay E, Matyashchuk E, Mussaffi H, Prais D, Steuer G, Mei-Zahav M, Hanahya S, Blau H.
Correlation between indices of spirometry and forced oscillation in sick children.
American Thoracic Society International Conference, New Orleans, Louisiana, USA, May 2010.
Am J Respir Crit Care Med. 2010;181:A3300.

56. Kaplan E, Bar Yishay E, Prais D, Mei-Zahav M, Mussaffi H, Steuer G, Matyashuk Y, Sirota L, Klinger G, Jabara N, Blau H.
Excellent pulmonary outcome for very low birth weight infants born in the post

Excellent pulmonary outcome for very low birth weight infants born in the post surfactant era.
American Thoracic Society International Conference, Denver, CO, USA, May 2011.
Am J Respir Crit Care Med. 2011;183:A3951.

57. Blau H.
Emerging infections in cystic fibrosis.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October, 2012.

58. Blau H.
Cystic fibrosis as a management model for chronic respiratory diseases. Symposium.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October, 2012.

59. Blau H.
The changing face of the cystic fibrosis clinic.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October, 2012.

60. Blau H.
Pulmonary function in children born with extreme prematurity. Plenary session.
The Society of Latin America Neumonology Pediatrica (SOLANEP) Meeting, Chile, October, 2012.

61. Rosenfeld S, Mantin H, Mussaffi H, Taizi T, Landau E, Kadosh D, Shapira M,
Roth D, Blau H.
Effect of Snoezlen on pain perception and anxiety in CF infants during sputum.
26th Annual North American Cystic Fibrosis Conference, Orlando, FL, USA, October 2012.

62. Mei-Zahav M, Ben Amitai D, Mussaffi H, Prais D, Stafler P, Blau H.
Propranolol therapy for capillary hemangioma in wheezy infants and children.
American Thoracic Society International Conference, Philadelphia, PA, USA, May 2013.
Am J Resp Crit Care Med. 2013;187:A4570.

63. Prais D, Kaplan E, Klinger G, Bar-Yishay E, Mei Zahav M, Mussaffi H, Steuer G, Sirota L, Blau H.
Long term effect of palivizumab immunization on children born <29 w gestation.
European Respiratory Society Annual Congress, Barcelona, Spain, September 2013.
Eur Respir J. 2013 42:Suppl 57, P4318.

64. Stafler P, Mei-Zahav M, Mussaffi H, Lavie M, Shoseyov D, Cohen-Cymbercnoh M, Gur M, Livnat G, Aviram M, Picard E, Prais D, Kerem E, Blau H.
Impact of CF population carrier screening: the Israel experience.
27th Annual North American Cystic Fibrosis Conference, Salt Lake City, Utah, October 2013; Pediatr Pulmonol. 2013: A469.

65. Stafler P, Weinreb S, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Bar-On O,
Blau H.
Lung clearance index- A new parameter for airway obstruction in acute bronchiolitis?

bronchiolitis?
European Respiratory Society Congress, Munich, Germany.
Eur Respir J. 2014; 44:Suppl 58, 188.

66. Blau H, Aviram M, Mussaffi H, Ben-Zvi H, Mei-Zahav M, Prais D, Stafler P, Steuer G, Mircus G, Greenberg D, Av-Gay Y, Tal A.
Safety and tolerability of nitric oxide given by inhalation to subjects with CF in a prospective, open label, phase IIA trial.
28th North American Cystic Fibrosis Conference, Atlanta, Georgia, USA, October 2014.
Pediatr Pulmonol. 2014: A226.

67. Mussaffi H, Fisch-Shvalb N, Ben-Zvi H, Mei-Zahav M, Livni G, Prais D, Stafler P, Steuer G, Taizi T, Blau H.
Clinical impact of beta-lactamase producing Enterobacteriaceae in sputum of CF patients.
28th North American Cystic Fibrosis Conference, Atlanta, Georgia, USA, October 2014.
Pediatr Pulmonol, 2014: A301.

68. Landau E, Kalamaro V, Taizi T, Kadosh D, Mantin H, Mussaffi H, Blau H.
The effect of a 12-month adherence intervention, “CF My Way“, on medication possession, clinical outcomes and quality of life in CF adolescents and young adults.
38th European Cystic Fibrosis Conference, Brussels, Belgium, June 2015.
J Cystic Fibros. 2015;14: S18.

69. Cohen-Cymberknoh M, Gilead N, Gartner S, Simanovski N, Canino E, Carreño JC, Blau H, Mussaffi H, et al.
Factors associated with failure to eradicate first or newly acquired *Pseudomonas aeruginosa* in patients with CF.
38th European Cystic Fibrosis Conference, Brussels, Belgium, June 2015.
J Cystic Fibros. 2015;14: S54.

70. Cohen-Cymberknoh M, Tanny T, Blau H, Kadosh D, Mussaffi H, Nir V, Bentur L, Shoseyov D, et al.
Prevalence and characteristics of attention deficit hyperactivity disorder (ADHD) in patients with cystic fibrosis (CF).
38th European Cystic Fibrosis Conference, Brussels, Belgium, June 2015.
J Cystic Fibros. 2015;14: S134.

71. Levine H, Cohen-Cymberknoh M, Klein N, Hoshen M, Mussaffi H, Breuer O, Kerem E, Blau H.
Asthma and bronchodilator use in patients with Cystic Fibrosis.
14th International Congress on Pediatric Pulmonology, Krakow, Poland
Pediatr Pulmonol. 2015. 50: S51, A80
Awarded Young Investigator Award for Outstanding Presentation to Dr. Hagit Levine, while a fellow under my supervision

72. Mussaffi H, Beeri Berkowiz R, Blau H, Mei-Zahav M, Stafler P, Prais D, Steuer G, Meyerovich J.
Predictors of the development of cystic fibrosis-related diabetes (CFRD).
29th Annual North American Cystic Fibrosis Conference, Phoenix, Arizona, USA, October 2015.
Pediatr Pulmonol. 2015;50 S41: A601.

73. Bar-On O, Mussaffi H, Ben-Zvi H, Mei-Zahav M, Prais D, Steuer G, Stafler P, Levine H, Blau H
Achromobacter xylosoxidans in cystic fibrosis patients: prevalence and clinical significance
39th ECFS conference, Basel, Switzerland, June 2016

Journal of Cystic Fibrosis, 2016;15:S75, A95

74. Mei-Zahav M, Mussaffi H, Efrati O, Blau H, Livnat G, Bentur L, Aviram M, Gur M, Kerem E
Improved outcome in cystic fibrosis – results of the Israeli CF Patient Registry 2005–2013
39th ECFS conference, Basel, Switzerland, June 2016
Journal of Cystic Fibrosis, 2016;15:S117, A256

75. Shteinberg M, Ben Lulu A, Blumenfeld Z, Gur M, Bentur L, Mussaffi H, Blau H, Sarouk I, Efrati O, Cohen-Cymberknoh M, Kerem E, Aviram M, Pickard E, Livnat G. Infertility among women with cystic fibrosis: prevalence and risk factors
39th ECFS conference, Basel, Switzerland, June 2016
Journal of Cystic Fibrosis, 2016;15:S108, A223

76. Stafler P, Mussaffi H, Prais, D, Steuer G, Blau H
Colistin in non Cystic Fibrosis Chronic Lung Disease
15th International Congress on Pediatric Pulmonology, Naples, Italy, June 2016
Pediatr Pulmonol 2016; 51: S67, C54

77. Wilschanski M, Dropiyvsky H, Efrati O, Bentur L, Livnat G, Picard E, Aviram M, Cohen M, Blau H.
Electrophysiological tests in CF diagnosis: nasal potential difference is more predictive than sweat test- single center study.
30th Annual North American Cystic Fibrosis Conference, Orlando, Florida, USA, October 2016.
Pediatr Pulmonol. 2016;51 S45: p 254, A163.

78. Stafler, P , Blau, H , Mussaffi, H , Rothstein, A , Lakovsky, Y, Atar, E, Bruckheimer, E, Itkin, M .
Kaposiform Pulmonary Lymphangiomatosis: a Systemic Disease Amenable To Mechanical Manipulation?
American Thoracic Society International Conference, Washington, DC, USA, May 2017
Am J Resp Crit Care Med. 2017;195:A6112.

79. Issachar A, Rosengarten D, Braun B, Blau H, Tur-Kaspa R, Cohen-Naftaly M, Sneh Arbib O, Shlomai A, Snir Y, Kremer M, Mei-Zahav M
Bevacizumab (Avastin) Treatment for severe Pulmonary Hypertension and High Cardiac Output Failure Secondary to Liver involvement in Patients with Hereditary Hemorhagic Telangiectasia.
The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017
Hepatology 66, 435A-435A

80. Nofar Amitai, Patrick Stafler, Huda Mussaffi, Meir Mei Zahav, Hannah Blau, Dario Prais
Long term effect of palivizumab immunization on children born before 29 weeks gestation
European Respiratory Society International Congress, Milano, Italy, September 2017
European Respiratory Journal 2017; 50 (suppl 61), PA2081

81. A Dagan, E Kerem, H Blau, L Bentur, Y Bezalel, O Efrati, G Livnat
Ivacaftor for the P.SER549ARG gating mutation –the Israeli experience
The 31st Annual North American Cystic Fibrosis Conference, Indianapolis, Indiana, USA. November, 2017
Pediatric Pulmonology 2017; 52:S302

82. E Kerem, H Blau, M Shteinberg, O Efrati, S Alon, B Amit, R Chertkoff, E Almon, L Fux, Y Shaaltiel, L Bentur
Development of novel actin inhibition resistant DNAse 1 enzyme- Alidornase alfa for the treatment of cystic fibrosis
The 31st Annual North American Cystic Fibrosis Conference, Indianapolis, Indiana, November, 2017
Pediatric Pulmonology 2017; 52:S254

83. H Dropiyvsky-Goldstein, Y Yaakov, H Blau, O Efrati, L Bentur, G Livnat, E Picard, M Aviram, R Machlin, M Wilschanski
Electrophysiological tests in CF diagnosis: nasal potential difference is more predictive than sweat test–single center study
40th ECFS Conference, Seville, Spain, June 2017
Journal of Cystic Fibrosis 2017; 16, S28

84. E Kerem, H Blau, M Shteinberg, O Efrati, S Alon, E Dekel, BC Amit, C Raul, E Brill-Almon, L Fux, Y Shaaltiel, L Bentur
Phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis
E Kerem, H Blau, M Shteinberg, O Efrati, S Alon, E Dekel, BC Amit, C Raul, ...
40th ECFS Conference, Seville, Spain, June 2017
Journal of Cystic Fibrosis 2017; 16, S1

85. T Tanny, O Breuer, H Blau, D Kadosh, H Mussaffi, S Gartner, A Salinas, L Bentur, V Nir, M Gur, D Shoseyov, E Kerem, I Berger, M Cohen-Cymberknoh
Prevalence and characteristics of attention deficit hyperactivity disorder in patients with cystic fibrosis
40th ECFS Conference, Seville, Spain, June 2017
Journal of Cystic Fibrosis 2017; 16, S40

86. K Akel, H Blau, Y Eshel, S Gruzovsky, Y Gendler, H Mussaffi, M Meizahav, D Prais, G Steuer, H Levine, P Stafler
Impact of Video-fluoroscopic Swallow Studies on Feeding Management and Clinical Status of Children with Dysphagia.
Pediatric Pulmonology 2017; 52: S155

G. OTHER PUBLICATIONS

Letter to the Editor

Stafler P, Mussaffi H, Gendler Y, **Blau H**.
Induced sputum versus broncho-alveolar lavage for pathogen surveillance in young cystic fibrosis patients: Low specificity is not necessarily a bad thing.
Pediatr Pulmonol. 2018 Jan; 53:8
(PEDIATRICS Q1, 19/120, IF 2.758)

Multicenter Studies

1. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group.
Genetic modifiers of liver disease in cystic fibrosis.
JAMA. 2009;302:1076-83.
(MEDICINE, GENERAL & INTERNAL 3/154, IF 35.289, No. of Citations 118)

:

2. Amirav I, Wallmeier J, Loges NT, Menchen T, Pennekamp P, Mussaffi H, Abitbul R, Avital A, Bentur L, Dougherty GW, Nael E, Lavie M, Olbrich

H, Werner C, Kintner C, Omran H; Israeli PCD Consortium Investigators. Systematic Analysis of CCNO Variants in a Defined Population: Implications for Clinical Phenotype and Differential Diagnosis. Hum Mutat. 2016; 37:396-405.
(GENETICS & HEREDITY 23/165, IF 5.089, No. of Citations 0)

3. Amirav I, Roduta Roberts M, Mussaffi H, Mandelberg A, Roth Y, Abitbul R, Luder A, Blau H, Alkrinawi S, Aviram M, Ben-Ami M, Rotschild M, Bentur L, Shoseyov D, Cohen-Cymberknoh M, Kerem E, Avital A, Springer C, Hevroni A, Dabbah H, Elizur A, Picard E, Goldberg S, Rivlin J, Livnat G, Lavie M, Alias N, Soferman R, Olbrich H, Raidt J, Wallmeier J, Werner C, Loges NT, Omran H.
Collecting clinical data in primary ciliary dyskinesia- challenges and opportunities. F1000Res. 2016 Aug 18;5:2031.

Standards of Practice

Standards of Practice for the European CF Society for the Clinical Trials Network: Induced Sputum for expectorating children and adults and non-expectorating young children
Mussaffi H and Blau H

H. REVIEWER, INTERNATIONAL JOURNALS

1. The Lancet Respiratory Medicine
2. American Journal Respiratory and Critical Care Medicine
3. European Respiratory Journal
4. CHEST Journal
5. Pediatrics
6. Journal of Cystic Fibrosis
7. Pediatric Pulmonology
8. Expert Respiratory Reviews
9. Journal of Inflammation
10. Critical Care Nursing
11. Disease Markers